Osborne Clarke is bringing even more expertise in pharmaceutical and biotech licensing law on board with the arrival of Dr Florian Reiling from Clifford Chance from 1 April.
The trend is clear: in recent years, many life sciences and healthcare companies have focused their strategic activities not only on M&A transactions but also on licence collaborations and other alliances. These transactions are extremely complex and need to be managed and negotiated by experienced licensing experts with in-depth industry and regulatory knowledge.
Osborne Clarke’s Life Sciences and Healthcare team has a specific focus on licensing and collaborations. The team is well-versed in the business, regulatory and commercial issues inherent in pharma and biotech licensing deals, and consists of intellectual property, regulatory, tax and antitrust specialists. Osborne Clarke’s licensing team in Germany is led by intellectual property specialists Dr Andrea Schmoll and Dr Tim Reinhard. In order to further expand the team’s breadth, Dr Florian Reiling joins Osborne Clarke Germany on April 1.
Florian Reiling, who was a counsel at Clifford Chance, has many years of expertise and an excellent reputation, particularly in cooperation, licence and R&D agreements, mainly in the life sciences and healthcare sector. This, together with his experience in leading IP teams in large M&A projects, perfectly complements the Osborne Clarke team. In addition, Florian has in-depth knowledge of IP-related advice on digital and AI-based business models, which fits in well with the firm's tech focus.
Our life sciences and healthcare sector has seen strong growth recently, with great potential ahead. With Florian Reiling's help, we're advancing towards our goal of becoming a top destination for transactions in this field, be it M&A, licensing, or R&D deals.
Corporate communications and press contacts
Connect with one of our experts
